#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)
hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides an unaudited trading update for the year ended 31 December 2024. Highlights · Revenue up 11.9% to £62.7 million (2023: £56.0 million) · EBITDA margin of c.26% (2023: 23.3%) · Cash of £44.2 million as at 31 December 2024 (31 December 2023: £37.0 million)…
Continue reading